Table 1.
Patient characteristics and whole exon sequencing results of tumor biopsies before and after decitabine plus camrelizumab combination therapy.
| Case 1 | Case 2 | Case 3 | ||
|---|---|---|---|---|
| Gender | M | F | F | |
| Age | 47 | 74 | 46 | |
| Stage at diagnosis | IV, metastatic | IV, metastatic | IV, metastatic | |
| Smoker | Yes | No | No | |
| EGFR mutations | No | L858R, T790M | No | |
| ALK mutations | No | No | No | |
| Before | TMB (Muts/Mb) | 7.83 | 2.49 | 1.91 |
| TNB (Neos/Mb) | 3.72 | 1.55 | 0.75 | |
| MSI (%) | L:1.91 | L:2.47 | L:4.72 | |
| HLA LOH | HLA-C:03*03 | HLA-A:33*03 HLA-B:44*03 HLA-C:07*06 | HLA-B:46*01 HLA-C:01*02 | |
| PD-L1 (%) | Positive | NR | Positive | |
| After | TMB (Muts/Mb) | 0.1 | 2.98 | 1.16 |
| TNB (Neos/Mb) | 0.03 | 1.32 | 0.45 | |
| MSI (%) | L:1.50 | L:1.91 | L:0.78 | |
| HLA LOH | HLA-C:03*03 | HLA-A:33*03 HLA-B:44*03 HLA-C:07*06 | HLA-B:46*01 HLA-C:01*02 | |
| PFS (months) | 5.4 | 6.8 | 6.5 | |
PFS, progression free survival; TMB, tumor mutation burden; TNB, tumor neoantigen burden; MSI, microsatellite instability; HLA LOH, HLA loss of heterozygous.